Galapagos NV headed into today's Q1 print as a stock that has spent months in a quiet holding pattern — and the numbers that landed yesterday evening confirmed why the market has been reluctant to move decisively in either direction.
The most interesting tension heading in was between a company sitting well below book value and one that keeps surprising on the earnings line. The price-to-book ratio was just 0.54 — less than 55 cents of market value for every euro of net assets — which tells a story of deep scepticism about the pipeline's ability to generate returns. Yet the EPS surprise factor ranked in the 91st percentile across the universe, and the 90-day EPS momentum score was in the 98th percentile. Galapagos has been beating on the bottom line with unusual consistency; the question was always whether revenue would follow.
The answer, at least in Q1, is not yet. The company reported EPS of $0.25, clearing the consensus estimate of -$1.27 by a wide margin. Revenue of $7.6M missed the $16M estimate. That divergence — a company burning through its cash base more slowly than feared, but still generating far less commercial revenue than the Street had pencilled in — has defined the Galapagos story ever since it lost the filgotinib US approval and restructured its collaboration with Gilead Sciences (which remains the single largest shareholder at 25.4% of shares). EV/EBITDA improved 0.15 points over the past month, but with enterprise value deeply negative at around -€1.4 billion, the standard valuation toolkit tells only a partial story here.
The ownership structure adds another layer. Tang Capital, the second-largest holder with 7.9% of shares, trimmed its position by 648,000 shares as of end-2025. That is a meaningful reduction from a firm whose involvement has long been read as a signal of confidence in the pipeline. EcoR1 Capital — a board-represented hedge fund — was actively buying in May and June 2025, accumulating over 250,000 shares at prices near current levels. That buyer was paying roughly €23–25 per share, close to where the stock trades today at €24.62, which has edged up 1.2% on the day and 2.7% over the week despite a 3.8% pullback on the month. Short positioning is minimal — SI is under 1% of free float and has trended lower since late March — making the stock's fate entirely dependent on fundamental conviction rather than technical squeeze dynamics. Borrow availability is ample, with cost to borrow at a modest 2.5%.
Today's print is therefore a test of whether the cash-preservation story — beating on EPS while clinical and commercial milestones remain uncertain — is enough to rebuild confidence in the long-term value of a balance sheet that the market has been pricing at a steep discount for several years.
See the live data behind this article on ORTEX.
Open GLPG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
